<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182373</url>
  </required_header>
  <id_info>
    <org_study_id>3357-101</org_study_id>
    <nct_id>NCT04182373</nct_id>
  </id_info>
  <brief_title>KW-3357 Study in Patients With Early Onset Severe Preeclampsia</brief_title>
  <official_title>A Phase 3, Randomized, Placebo-controlled, Double Blind Study of KW-3357 in Patients With Early Onset Severe Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Blood Products Organization</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with
      early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days of maintaining pregnancy</measure>
    <time_frame>Subjects will be observed until maternal and/or fetal indications for delivery necessitate cessation of expectant management or until approximately 34 0/7 weeks of gestation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of achievement of 32 weeks of gestation</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of achievement of 34 weeks of gestation</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of achievement of 28 weeks of gestation in subjects enrolled in the period of less than 28 weeks of gestation</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AT activity</measure>
    <time_frame>From baseline to Day 8 at all time points and 3 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PLT concentration</measure>
    <time_frame>From baseline to Day 8 at all time points and 3 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on D-dimer concentration</measure>
    <time_frame>From baseline to Day 8 at all time points</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FDP concentration</measure>
    <time_frame>From baseline to Day 8 at all time points</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sitting systolic blood pressure and sitting diastolic blood pressure</measure>
    <time_frame>From baseline to Day 8 at each time point, 3 days after termination of pregnancy, and 28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria/creatinine ratio</measure>
    <time_frame>From baseline to Day 8 at each time point, 3 days after termination of pregnancy, and 28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of blood lost during delivery</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biophysical Profile Score</measure>
    <time_frame>From baseline to Day 8 at each time point</time_frame>
    <description>Minimum is 0, max is 10. Higher score means better condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal growth rate</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score</measure>
    <time_frame>At 1 minute and 5 minutes after birth</time_frame>
    <description>Minimum is 0, max is 10. Higher score means better condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of neonatal asphyxia</measure>
    <time_frame>At 1 minute and 5 minutes after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal growth</measure>
    <time_frame>28 days before the end of study</time_frame>
    <description>Fetal growth is classified into small for gestational age (SGA), appropriate for gestational age (AGA), and large for gestational age (LGA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head and chest circumferences at birth</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term prognosis of neonates (incidence of bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukolame, retinopathy of prematurity, sepsis, necrotizing enteritis, death, etc)</measure>
    <time_frame>28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of neonates who was hospitalized in the NICU</measure>
    <time_frame>28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days in the NICU</measure>
    <time_frame>28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of neonates with respiratory management at the time of admission to the NICU</measure>
    <time_frame>28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days of respiratory management at the time of admission to the NICU</measure>
    <time_frame>28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in TNF-alpha at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in interleukin (IL)-6 at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in IL-10 at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in hs-CRP at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in sFlt-1 at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in PlGF at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in sFlt-1/PlGF at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pulsatility index of the umbilical artery and middle cerebral artery</measure>
    <time_frame>At the time of examination from baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in findings of the umbilical artery and middle cerebral artery</measure>
    <time_frame>At the time of examination from baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Distribution of reasons for termination of pregnancy</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Prolongation days of pregnancy by reason of termination of pregnancy</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence or absence of stillbirth</measure>
    <time_frame>28 days before the end of study. Neonates will be assessed after delivery.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Placental weight</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence or absence of placental infarction</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Umbilical arterial blood gas at termination of pregnancy</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence or absence of HELLP syndromes and onset of symptoms</measure>
    <time_frame>During the course of the clinical trial. Period from the day of commencement of administration of the investigational drug to Day 28 after the delivery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>KW-3357</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>72 IU/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombin gamma</intervention_name>
    <description>Intravenous infusion, once a day, 7 days</description>
    <arm_group_label>KW-3357</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>physiological saline</intervention_name>
    <description>Intravenous infusion, once a day, 7 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who gave written consent to participate in the clinical trial by their own
             free will.

          2. Patients aged 20 years or older at the time of obtaining informed consent

          3. Patients with early-onset PE* 24 weeks 0 days to 31 weeks 6 days of gestation at the
             time of enrollment

             *: Determine the definition of gestational age based on the &quot;Guidelines for Obstetrics
             and Gynecology, Obstetrics, 2017&quot;

          4. Patients diagnosed with severe PE*

             *: Follow the diagnostic criteria of the Japan Society for the Study of Hypertension
             in Pregnancy

          5. Patients with AT activity of 100% or less in the preliminary examination

        Exclusion Criteria:

          1. Patients who are judged to require immediate delivery*

             *&quot;Best Practice Guide 2015 for Care and Treatment of Hypertension in Pregnancy&quot;
             Requirements for Considering Pregnancy Termination Regardless of Pregnancy Weeks in
             Pregnancy-induced Hypertension Syndrome Cases will be consulted for judgment.

          2. Patients with right hypochondralgia or epigastralgia

          3. Patients with HELLP syndromes

          4. Patients with pulmonary edema

          5. Patients with severe pleural effusion, severe ascites, or serous retinal detachment

          6. Patients with central nervous system disorders (eclampsia, stroke) or visual disorders
             (cortical blindness)

          7. Patients with severe headache or urge eclampsia

          8. Patients with abruptio placentae

          9. Suspected patients with 8 or more obstetric DIC scores

         10. Patients with a definitive diagnosis of congenital AT deficiency

         11. Patients with diseases or symptoms other than the primary disease requiring immediate
             delivery

         12. Patients on ongoing treatment with nonsteroidal anti-inflammatory drugs (NSAIDs, e.g.,
             aspirin) or who require NSAIDs use during the course of the study.

         13. Patients who have received the following drugs within 72 hours before administration
             of the investigational product, etc., or who require administration of the following
             drugs during the study period (from the start of administration of the investigational
             product, etc., until the date of termination of pregnancy); heparin,
             low-molecular-weight heparin (e.g., enoxaparin or dalteparin), fondaparinux,
             antiplatelet drugs (e.g., clopidogrel, prasugrel, aspirin), direct thrombin inhibitors
             (e.g., dabigatran), or anticoagulants (e.g., AT preparations).

         14. Patients with a current or past history of serious drug allergy

         15. Patients with a history or complication of drug dependence or alcoholism

         16. Patients with hypersensitivity to AT preparations

         17. Patients who are pregnant with a fetus with a chromosomal abnormality or a fetus
             suspected of having a serious malformation syndrome

         18. Patients with multiple pregnancies

         19. Patients with a history or complication of antiphospholipid antibody syndrome

         20. Patients with diabetes complicated pregnancy, obvious diabetes mellitus, or insulin
             use

         21. Patients with uncontrollable or significant complications, including the following

               -  Clinically significant cardiovascular diseases, etc. (New York Heart Association
                  cardiac function classifications Class III or higher)

               -  Serious hepatic disease

               -  Serious renal disease

               -  Pneumonia, interstitial lung disease or other severe respiratory disease

               -  Blood disorders such as idiopathic thrombocytopenic purpura

               -  Psycho-central nervous system disorders that may affect informed consent

               -  Endocrine disorders such as hyperthyroidism

               -  Autoimmune diseases such as systemic lupus erythematosus

         22. Patients with active malignancy or patients with a history of onset or treatment of
             malignancy within 5 years before pregnancy (excluding excised or surgically cured
             basal cell carcinoma of the skin, squamous cell carcinoma of the skin or ductal
             carcinoma of the breast)

         23. Patients with active infections (e.g., toxoplasma infection, genital chlamydia,
             genital herpes, cytomegalovirus infection)

         24. Patients with a positive history for HIV antibody. Patients with a positive history
             for HBs antigen and HCV antibody and with active infection presenting with hepatitis
             symptoms.

         25. Patients with any of the following laboratory abnormalities in preliminary
             examinations; Patients with AST or ALT 2 times the upper limit of the reference level
             of the trial site; Cr &gt;=1.1 mg/dL

         26. Patients who have participated in a clinical trial or equivalent study of a drug or
             medical device within 4 months before pregnancy (within 6 months for biologics) and
             have received the investigational drug or used an unapproved medical device

         27. Other patients whom the principal investigator or the subinvestigator judges to be
             unfavorable for participation in the clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyowa Kirin Co., Ltd</last_name>
    <phone>+81-3-5205-7200</phone>
    <email>clinical.info.jp@kyowakirin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Juntendo University Shizuoka Hospital</name>
      <address>
        <city>Izunokuni</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Antithrombin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

